This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Varian Medical Systems Receives FDA 510(k) Clearance For Vitesse™ Brachytherapy Treatment Planning Software

PALO ALTO, Calif., Jan. 24, 2013 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) has received an FDA 510(k) clearance for the latest version of its Vitesse™ real time planning for HDR brachytherapy which is used to plan and perform high-dose-rate (HDR), ultrasound-guided brachytherapy treatments for prostate cancer. 

"This version of Vitesse reduces the number and complexity of steps involved in planning and completing a treatment. It eliminates the need for a data transfer to another software program, and avoids moving the patient to a CT scanner for images in the middle of the procedure. For these reasons, most clinicians will see a reduction in the amount of time needed to complete these treatments, often by as much as an hour and a half," said Tim Clark, marketing manager for Varian BrachyTherapy.

HDR brachytherapy involves delivering radiotherapy from inside the body by temporarily placing a tiny radioactive source directly into the tumor or other targeted area. Using a robotic device called an afterloader, clinicians place the radioactive source into positions through needles that have been inserted into the area being treated. The source is then moved within the needles under computer control to create the specified dose distribution within the patient's anatomy. 

Using the latest version of Vitesse, HDR brachytherapy treatment plans can be created in a real-time environment, using ultrasound images generated in the operating room rather than CT scans generated elsewhere. This avoids the need to move the patient to a CT scanner room for imaging after the needles have been put in place. The process can now be completed entirely within the Vitesse program, from capturing the ultrasound image to finalizing an approved treatment plan.

In addition to receiving FDA 510(k) clearance which permits sale of the Vitesse software in the United States, Varian has also obtained the CE Mark which permits sales in the European Union and other countries where the CE Mark is recognized.

About Varian Medical Systems Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes, digital detectors, and image processing workstations for X-ray imaging in medical, scientific, and industrial applications and also supplies high-energy X-ray devices for cargo screening and non-destructive testing applications. Varian Medical Systems employs approximately 6,200 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com or follow us on Twitter.   

FOR INFORMATION CONTACT:

Varian Medical Systems, United States Meryl Ginsberg, 650.424.6444 meryl.ginsberg@varian.com

SOURCE Varian Medical Systems

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,024.91 -73.54 -0.43%
S&P 500 1,996.25 -7.12 -0.36%
NASDAQ 4,580.5860 +0.3150 0.01%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs